NASDAQ:HZNP

Rule 17(e) Announcement - Horizon Therapeutics plc

Retrieved on: 
星期五, 十月 6, 2023
Biotechnology, Pharmaceutical, Health, Knowledge, Amgen, K.G.F: Chapter 1, Scheme, Form 10-K, Annual report, Part, Acquisition, Risk, The Company, Horizon Therapeutics, Security (finance), Horizon

Trading of Horizon Shares on the Nasdaq Global Select Market ("Nasdaq") was halted with effect from 8:00 p.m.

Key Points: 
  • Trading of Horizon Shares on the Nasdaq Global Select Market ("Nasdaq") was halted with effect from 8:00 p.m.
  • The directors of Horizon accept responsibility for the information contained in this announcement.
  • This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Horizon assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Rule 17(d) Announcement – Horizon Therapeutics plc

Retrieved on: 
星期四, 十月 5, 2023
Biotechnology, Pharmaceutical, Health, Irish Takeover Panel, Horizon Therapeutics, Knowledge, Amgen, Registrar of Companies (India), High court, Court, Proxy, K.G.F: Chapter 1, Transaction, Scheme, Effective date, Form 10-K, Person, Annual report, Part, Order, Risk, Registrar, The Company, Holding company, Security (finance), Cryptocurrency, Horizon

The directors of Horizon accept responsibility for the information contained in this announcement.

Key Points: 
  • The directors of Horizon accept responsibility for the information contained in this announcement.
  • This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Horizon assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
  • Neither the contents of Horizon's website nor the contents of any other website accessible from hyperlinks are incorporated into, or form part of, this announcement.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
星期二, 十月 3, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a sibling of a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
星期二, 十月 3, 2023
Biotechnology, Pharmaceutical, Health, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
星期一, 十月 2, 2023
General Health, Finance, Health, Professional Services, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
星期一, 十月 2, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

Retrieved on: 
星期一, 十月 2, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Civil service commission, ANVISA, Azathioprine, Multiple sclerosis, Congress, European Commission, Evaluation, CEST, Brazilian Health Regulatory Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Treatment, Food, Pharmaceutical industry, NMOSD, Inebilizumab, Patient

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023, Oct. 11-13.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023, Oct. 11-13.
  • UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the U.S. Food and Drug Administration, the European Commission and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of NMOSD in adults who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+).
  • P015: Association of Cytokine Proteins with Disease Activity in NMOSD Participants Receiving Inebilizumab Treatment (S. Pittock)
    P409: Long-Term Comparative Efficacy of Inebilizumab in the AQP4+ Subpopulation from the N-MOmentum Open-Label Extension Versus Azathioprine and Immunosuppressive Therapies and Versus Placebo in Patients with NMOSD (B. Cree)
    P011: Matching-Adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-Term Effectiveness (F. Paul)
    Horizon will host a symposium Thursday, Oct. 12 from 8:45 to 9:45 a.m. CEST, “Looking for unrecognized disease activity in NMOSD to optimize treatment choice and prevent disability,” chaired by Massimo Filippi, M.D., Ph.D., featuring presentations from Maria Rocca, M.D., Orhan Aktas, M.D.
  • and Jeffrey Bennett, M.D., Ph.D.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
星期五, 九月 29, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes

Retrieved on: 
星期五, 九月 29, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, Science, American Thyroid Association, ATA, Undisrupted, COVID-19, Medicine, QOL, Patient, CAS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, D.C, TED, Pharmaceutical industry

An analysis examined whether patients who experience a treatment disruption, defined as a >60-day gap between consecutive infusions, are more likely to need a second course of treatment.

Key Points: 
  • An analysis examined whether patients who experience a treatment disruption, defined as a >60-day gap between consecutive infusions, are more likely to need a second course of treatment.
  • Undisrupted patients (n=4,230) and disrupted patients (n=1,155) were observed for one year after the initial full course of treatment.
  • The analysis looked at baseline GO-QOL data for 171 moderate-to-severe TED patients prior to treatment in two clinical trials.
  • “The data presented this weekend help us further our mission of ensuring those in the Thyroid Eye Disease community receive appropriate care.”

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
星期三, 九月 27, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.